• Je něco špatně v tomto záznamu ?

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

L. Arcaini, T. Lamy, J. Walewski, D. Belada, J. Mayer, J. Radford, W. Jurczak, F. Morschhauser, J. Alexeeva, S. Rule, J. Cabeçadas, E. Campo, SA. Pileri, T. Biyukov, M. Patturajan, ML. Casadebaig Bravo, M. Trnĕný, . ,

. 2018 ; 180 (2) : 224-235. [pub] 20171128

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010258

In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010258
003      
CZ-PrNML
005      
20180404141922.0
007      
ta
008      
180404s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.15025 $2 doi
035    __
$a (PubMed)29193019
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Arcaini, Luca $u Department of Molecular Medicine, University of Pavia, Pavia, Italy. Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
245    10
$a Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma / $c L. Arcaini, T. Lamy, J. Walewski, D. Belada, J. Mayer, J. Radford, W. Jurczak, F. Morschhauser, J. Alexeeva, S. Rule, J. Cabeçadas, E. Campo, SA. Pileri, T. Biyukov, M. Patturajan, ML. Casadebaig Bravo, M. Trnĕný, . ,
520    9_
$a In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antitumorózní látky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x mortalita $x patologie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a recidiva $7 D012008
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a thalidomid $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D013792
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lamy, Thierry $u Department of Haematology, Hôpital Pontchaillou, Rennes, France.
700    1_
$a Walewski, Jan $u Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland.
700    1_
$a Belada, David $u Fourth Department of Internal Medicine, Haematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Haematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Radford, John $u The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
700    1_
$a Jurczak, Wojciech $u Department of Haematology, Jagiellonian University Medical College, Kraków, Poland.
700    1_
$a Morschhauser, Franck $u Department of Haematology, Hôpital Claude Huriez, EA 7365 GRITA, Lille, France.
700    1_
$a Alexeeva, Julia $u Department of Haematology Research, Federal Medical Research Centre, Saint Petersburg, Russia.
700    1_
$a Rule, Simon $u Department of Haematology, Derriford Hospital, Plymouth, United Kingdom.
700    1_
$a Cabeçadas, José $u Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
700    1_
$a Campo, Elias $u Haematopathology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.
700    1_
$a Pileri, Stefano A $u Unit of Haematopathology, European Institute of Oncology, Milan, Italy.
700    1_
$a Biyukov, Tsvetan $u Clinical Research and Development, Celgene Sàrl, Boudry, Switzerland.
700    1_
$a Patturajan, Meera $u Clinical Research and Development, Celgene Corporation, Summit, NJ, USA.
700    1_
$a Casadebaig Bravo, Marie-Laure $u Clinical Research and Development, Celgene Sàrl, Boudry, Switzerland.
700    1_
$a Trnĕný, Marek $u Department of Haematology, Charles University Hospital, Prague, Czech Republic.
700    1_
$a ,
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 180, č. 2 (2018), s. 224-235
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29193019 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142002 $b ABA008
999    __
$a ok $b bmc $g 1287743 $s 1007070
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 180 $c 2 $d 224-235 $e 20171128 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace